Abstract
Objective or Purpose Primary open-angle glaucoma (POAG) is a highly heritable disease with 127 identified risk loci. Polygenic risks score (PRS) offers a measure of aggregate genetic burden. In this study, we assess whether PRS improves risk stratification in patients with ocular hypertension.
Design A post-hoc analysis of the Ocular Hypertension Treatment Study (OHTS) data.
Setting, Participants, and/or Controls 1636 participants were followed from 1994 to 2020 across 22 sites. The PRS was computed for 1009 OHTS participants using summary statistics from largest cross-ancestry POAG metanalysis with weights trained using 8,813,496 variants from 488,395 participants in the UK Biobank.
Methods, Interventions, or Testing Survival regression analysis, with endpoint as development of POAG, predicted disease onset from PRS incorporating baseline covariates.
Main Outcomes and Measures Outcome measures were hazard ratios for POAG onset. Concordance index and time-dependent AUC were used to compare the predictive performance of multivariable Cox-Proportional Hazards models.
Results Mean PRS was significantly higher for POAG-converters (0.24 ± 0.95) than for non-converters (- 0.12 ± 1.00) (p < 0.01). POAG risk increased 1.36% with each higher PRS decile, with conversion ranging from 9.5% in the lowest PRS decile to 21.8% in the highest decile. Comparison of low-and high-risk PRS tertiles showed a 1.8-fold increase in 20-year POAG risk for participants of European and African ancestries (p<0.01). In the subgroup randomized to delayed treatment, each increase in PRS decile was associated with a 0.52-year decrease in age at diagnosis, (p=0.05). No significant linear relationship between PRS and age at POAG diagnosis was present in the early treatment group. Prediction models significantly improved with the addition of PRS as a covariate (C-index = 0.77) compared to OHTS baseline model (C-index=0.75) (p<0.01). One standard deviation higher PRS conferred a mean hazard ratio of 1.25 (CI=[1.13, 1.44]) for POAG onset.
Conclusions Higher PRS is associated with increased risk for, and earlier development of POAG in patients with ocular hypertension. Early treatment may mitigate the risk from high genetic burden, delaying clinically detectable disease by up to 5.2 years. The inclusion of a PRS improves the prediction of POAG onset.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT00000125
Clinical Protocols
https://ohts.wustl.edu/results/
Funding Statement
- NEI K23EY032634 - NEI R01EY032559 - Research to Prevent Blindness Career Development Award - American Glaucoma Society Clinician Scientist Award - The Glaucoma Foundation (NYC)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Mass General Brigham name waived ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Meeting presentation: Accepted for American Glaucoma Society 2023 Meeting
Financial support: NEI K23EY032634 grant, NEI R01EY032559, Research to Prevent Blindness Career Development Award, American Glaucoma Society Clinician Scientist Award, and The Glaucoma Foundation (NYC). The sponsors or funding organizations had no role in the design or conduct of this research.
Conflict of interest: Dr. Pasquale is a consultant for Twenty Twenty and Character Biosciences
Data Availability
Genomic data from OHTS is available online through the National Eye Institute. The remainder of the OHTS data set will be made available at the NEI Data Commons.
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000240.v1.p1